Arthrosurface, located in Franklin, MA, develops and markets orthopedic devices for joint resurfacing. Boston Millennia Partners sourced this investment opportunity through proactive deal flow efforts. We have maintained our position as the sole institutional investor in Arthrosurface because we believe strongly in the future prospects for the company’s novel solutions in a rapidly expanding orthopedics market. The company has been growing rapidly, with surgeon usage and revenue growth rates over 400% cumulatively over the past three years. The company’s proprietary HemiCAP® (Contoured Articular Prosthetic) system is a unique, minimally invasive technology that can be used to treat a wide range of joint defects ranging from isolated defects on the joint’s articular surface to large articular surface lesions and osteochondral defects. Arthrosurface has developed a broad portfolio of FDA-approved implant devices for the shoulder, knee and hip joints, as well as the great toe and ankle joints. In addition, the Company has several implant devices under development targeting the knee (Uni) and glenoid surface of the shoulder. Arthrosurface markets and distributes its products in the U.S. and several countries outside of the U.S., including Germany, the U.K., Spain, Italy, Belgium, Australia, Canada and South Africa.

Related News
Patellofemoral Arthroplasty: Inlay vs. Onlay
A recent study, published in the KSSTA journal, compared two different implant types used in Patellofemoral Arthroplasty (PFA): Group I consisted of an inlay (HemiCAP® Wave, Arthrosurface, Franklin, MA) Group II was based on an onlay design (2nd generation, Journey™ PFJ, Smith & Nephew, Andover, MA) Read Full Release